The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|September 13, 2022
Rheumatoid Arthritis Quiz: Breastfeeding and RA
Author(s)Lana Pine
New mothers are understandably nervous about taking medication while breastfeeding. Which treatments are appropriate for breastfeeding women with rheumatoid arthritis? Test your knowledge with this quiz.
Advertisement
What proportion of women with RA who hold treatment stop breastfeeding because disease activity becomes so severe?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement